FDA’s Psychedelic Push: Corporate Capture of Mental Health Solutions Amidst Crisis of Care
Original framing: “FDA's Makary on Trump EO to Ease Access to Psychedelics” — Bloomberg
It references the recent executive order without situating it within the longer history of psychedelic prohibition, the 1960s counter‑culture backlash, and earlier exploitative research on marginalized groups. The pattern of extracting value from vulnerable communities resurfaces in the current corporate push.
The FDA's psychedelic push illustrates a convergence of scientific ambition, corporate profit, and a historic pattern of extracting Indigenous knowledge without reciprocity.
While the narrative celebrates a regulatory breakthrough, it obscures the marginalised voices, cultural dimensions, and future risks of a commodified quick‑fix. By integrating Indigenous stewardship, transparent governance, and trauma‑informed care, we can re‑orient psychedelic medicine toward a systemic model that honors both scientific rigor and cultural integrity, averting the trickster paradox of healing through exploitation.